Potentiation of bleomycin in Jurkat cells by fungal pycnidione

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 1, 2012, Pages 18-28

  Kaneko, Mayumi ^a   Matsuda, Daisuke ^a   Ohtawa, Masaki ^a   Fukuda, Takashi ^a   Nagamitsu, Tohru ^a   Yamori, Takao ^b   Tomoda, Hiroshi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Bleomycin; G2 arrest; Pycnidione

Indexed keywords

BLEOMYCIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 1; FUNGAL EXTRACT; HISTONE H2AX; PYCNIDIONE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; FUNGUS; FUNGUS CULTURE; GLOEOTINIA; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ASCOMYCOTA; BIOLOGICAL AGENTS; BLEOMYCIN; CDC2 PROTEIN KINASE; CELL CYCLE CHECKPOINTS; DOWN-REGULATION; DRUG SYNERGISM; G2 PHASE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; JURKAT CELLS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TROPOLONE;

EID: 84855645507     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.18     Document Type: Article

References (48)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science, 266, 1821-1828 (1994).
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331 (1997).
3. Suganuma M, Kawabe T, Hori H, Funabiki T, Okamoto T. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res., 59, 5887-5891 (1999).
4. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J., 17, 159-169 (1998).
5. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science, 282, 1893-1897 (1998).
6. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science, 277, 1497-1501 (1997).
7. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol. Cell, 28, 739-745 (2007).
8. Blasina A, de Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol., 9, 1-10 (1999).
9. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J., 16, 545-554 (1997).
10. 2 DNA damage checkpoint targets both Wee1 and Cdc25. J. Cell Sci., 113, 1727-1736 (2000).
11. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 2, 791-797 (1996).
12. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res., 58, 3248-3253 (1998).
13. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ., 6, 927-936 (1995).
14. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res., 60, 566-572 (2000).
15. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res., 63, 31-35 (2003).
16. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res., 59, 4375-4382 (1999).
17. 2 checkpoint abrogator. Cancer Res., 61, 8211-8217 (2001).
18. Sha SK, Sato T, Kobayashi H, Ishigaki M, Yamamoto S, Sato H, Takada A, Nakajyo S, Mochizuki Y, Friedman JM, Cheng FC, Okura T, Kimura R, Kufe DW, Vonhoff DD, Kawabe T. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol. Cancer Ther., 6, 147-153 (2007).
19. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther., 7, 2955-2966 (2008).
20. Arai M, Sato H, Kobayashi H, Suganuma M, Kawabe T, Tomoda H, Omura S. Selective inhibition of bleomycin-induced G2 cell cycle checkpoint by simaomicin alpha. Biochem. Biophys. Res. Commun., 317, 817-822 (2004).
21. Arai M, Koizumi Y, Sato H, Kawabe T, Suganuma M, Kobayashi H, Tomoda H, Omura S. Boromycin abrogates bleomycin-induced G2 checkpoint. J. Antibiot., 57, 662-668 (2004).
22. Hagimori K, Fukuda T, Hasegawa Y, Omura S, Tomoda H. Fungal malformins inhibit bleomycin-induced G2 checkpoint in Jurkat cells. Biol. Pharm. Bull., 30, 1379-1383 (2007).
23. Pittayakhajonwut P, Theerasilp M, Kongsaeree P, Rungrod A, Tanticharoen M, Thebtaranonth Y. Pughiinin A, a sesquiterpene from the fungus Kionochaeta pughii BCC 3878. Planta Med., 68, 1017-1019 (2002).
24. Harris GH, Hoogsteen K, Silverman KC, Raghoobar SL, Bills GF, Lingham RB, Smith JL, Dougherty HW, Cascales C, Peláez F. Isolation and structure determination of pycnidione, A novel bistropolone stromelysin inhibitor from a Phoma sp. Tetrahedron, 49, 2139-2144 (1993).
25. Wright AD, Lang-Unnasch N. Potential antimalarial lead structures from fungi of marine origin. Planta Med., 71, 964-966 (2005).
26. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res., 59, 4042-4049 (1999).
27. Matsuda D, Nakayama Y, Horimoto S, Kuga T, Ikeda K, Kasahara K, Yamaguchi N. Involvement of Golgi-associated Lyn tyrosine kinase in the translocation of annexin II to the endoplasmic reticulum under oxidative stress. Exp. Cell Res., 312, 1205-1217 (2006).
28. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 30, 630-641 (2005).
29. Burgess A, Wigan M, Giles N, Depinto W, Gillespie P, Stevens F, Gabrielli B. Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J. Biol. Chem., 281, 9987-9995 (2006).
30. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell, 78, 773-785 (1994).
31. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res., 61, 8194-8202 (2001).
32. Sun Y, Xu Y, Roy K, Price BD. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol. Cell. Biol., 27, 8502-8509 (2007).
33. Rao VA, Agama K, Holbeck S, Pommier Y. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage. Cancer Res., 67, 9971-9979 (2007).
34. Renault G, Malvy C, Venegas W, Larsen AK. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol. Appl. Pharmacol., 89, 281-286 (1987).
35. Kubota T, Fujita S, Kodaira S, Yamamoto T, Josui K, Arisawa Y, Suto A, Ishibiki K, Abe O, Mabuchi K, Fuse M. Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn. J. Cancer Res., 82, 476-482 (1991).
36. Bagli JF, Bogri T, Palameta B, Martel R, Robinson W, Pugsley T, Lippmann W. Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters. J. Med. Chem., 22, 1186-1193 (1979).
37. Roca J. Topoisomerase II: a fitted mechanism for the chromatin landscape. Nucleic Acids Res., 37, 721-730 (2009).
38. Etiévant C, Kruczynski A, Barret JM, Perrin D, Hill BT. Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II. Biochem. Pharmacol., 65, 755-763 (2003).
39. Feng JM, Zhu H, Zhang XW, Ding J, Miao ZH. Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity. Cancer Biol. Ther., 7, 1726-1731 (2008).
40. 2 arrest through the ATM-Activated Chk2-executed pathway in HCT116 cells. Neoplasia, 11, 1226-1234 (2009).
41. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, Abraham RT. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell, 19, 607-618 (2005).
42. Denny WA. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin. Investig. Drugs, 6, 1845-1851 (1997).
43. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol. Cancer, 8, 34 (2009).
44. Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA. Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J. Biol. Chem., 283, 21382-21393 (2008).
45. Sturgeon CM, Cinel B, Díaz-Marrero AR, McHardy LM, Ngo M, Andersen RJ, Roberge M. Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones. Cancer Chemother. Pharmacol., 61, 407-413 (2008).
46. Roberge M, Berlinck RG, Xu L, Anderson HJ, Lim LY, Curman D, Stringer CM, Friend SH, Davies P, Vincent I, Haggarty SJ, Kelly MT, Britton R, Piers E, Andersen RJ. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res., 58, 5701-5706 (1998).
47. Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, Hutchins JR, Clarke PR, Zhou BB, Lees-Miller SP, Andersen RJ, Roberge M. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem., 276, 17914-17919 (2001).
48. Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia, 2, 261-272 (2000).